Insights on Health Care Transactions

With 2025 underway, the AFS Health Care team highlights some of the most pressing legal issues facing the health care industry this year.

On September 28, California Governor Gavin Newsom vetoed Assembly Bill (AB) 3129. The proposed law sought to regulate health care transactions involving private equity and hedge funds.

Recent events have caused hospitals and health systems nationwide to contemplate more robust participation in the long term care (LTC) sector, whether through modified ownership, joint venturing, clinical affiliation, or third-party management.

On March 5, the Federal Trade Commission (FTC), the US Department of Justice (DOJ) Antitrust Division, and the US Department of Health and Human Services (HHS) launched a cross-government inquiry into the role private equity firms, other alternative asset managers, health systems, and private payers play in health care transactions.

With 2024 underway, ArentFox Schiff highlights 10 of the most pressing legal issues facing the health care industry this year.

ArentFox Schiff advised Kindeva Drug Delivery in its combination with Meridian Medical Technologies.

ArentFox Schiff represented NorthView Acquisition Corp., a publicly traded special purpose acquisition company, in its merger with Profusa, Inc., a digital health company.

Health Care Partner Stephanie Trunk will present twice at the Informa Medicaid Drug Rebate Program Summit on October 12-14.

In Advisory Opinion 22-17, the US Department of Health and Human Services (HHS) Office of Inspector General (OIG) concluded that a proposed restructuring of a loan and other contractual relationships between a health system and a federally qualified health center (FQHC) “look-alike” clinic.

On August 19, 2022, the US Departments of Health and Human Services, Labor, and Treasury, as well as the Office of Personnel Management, released a highly-anticipated final rule clarifying the procedures and considerations for resolving disputes related to surprise medical bills.

Back in 2017, the state of Nevada passed a sweeping bill into law that addressed not only drug pricing transparency, but also reporting obligations applicable to pharmacy benefit managers and non-profit organizations and also imposed certain requirements on manufacturer sales forces.